CARM (CARISMA Therapeutics) Debt-to-Equity: -0.88 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CARISMA Therapeutics Debt-to-Equity?

CARISMA Therapeutics CARM -47.83% Debt-to-Equity is -0.88 as of Sep. 2025. The stock has 3 warning signs investors should review. Among 958 Biotechnology companies, CARISMA Therapeutics ranks worse than 104384.03% on this metric.

CARISMA Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.15 Mil. CARISMA Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.61 Mil. CARISMA Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2025 was $-0.87 Mil. CARISMA Therapeutics's debt to equity for the quarter that ended in Sep. 2025 was -0.88.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CARISMA Therapeutics's Debt-to-Equity or its related term are showing as below:

CARM' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.72   Med: 0.06   Max: 22.69
Current: -0.88

During the past 5 years, the highest Debt-to-Equity Ratio of CARISMA Therapeutics was 22.69. The lowest was -2.72. And the median was 0.06.

CARM's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs CARM: -0.88

CARISMA Therapeutics  (OTCPK:CARM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CARISMA Therapeutics Debt-to-Equity Related Terms

CARISMA Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Debt-to-Equity Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
0.10 0.23 -0.26 0.12 -0.09

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.09 -0.06 -0.04 -0.88

CARM vs SIGY, CNBX, LIPO: Debt-to-Equity Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Debt-to-Equity falls into.


CARISMA Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CARISMA Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.737 + 0.744) / -27.909
=-0.09

CARISMA Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.153 + 0.609) / -0.867
=-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.88 mean?
CARISMA Therapeutics (CARM) has a Debt-to-Equity of -0.88 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #999999 out of 958 companies in the Biotechnology industry.
Is CARISMA Therapeutics' Debt-to-Equity too high?
CARISMA Therapeutics' current Debt-to-Equity is -0.88. Based on the distribution chart, CARISMA Therapeutics ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CARISMA Therapeutics' Debt-to-Equity compare to SIGY and CNBX?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #999999 out of 958 companies for Debt-to-Equity. This places CARISMA Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CARISMA Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARISMA Therapeutics's current Debt-to-Equity is -0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.00 — trading 100% below its estimated fair value. The current Debt-to-Equity is -0.88. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Debt-to-Equity is -0.88 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.